LONDON, August 27, 2014 /PRNewswire/ --
On Tuesday, August 26, 2014, the NASDAQ Composite ended at 4,570.64, up 0.29%, the Dow Jones Industrial Average finished the day 0.17% higher at 17,106.70, and the S&P 500 closed at 2,000.02, up 0.11%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.62, up 0.41%, and the index has advanced 7.97% in the last three months. Investor-Edge has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Thermo Fisher Scientific Inc. (NYSE: TMO), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Vical Inc. (NASDAQ: VICL), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:
Pacific Biosciences of California Inc.'s stock finished Tuesday's session 2.30% higher at $5.34. A total of 0.46 million shares were traded, which was below its three months average volume of 0.61 million shares. The stock moved between $5.12 and $5.35 during the session. Over the last one month and the previous three months, Pacific Biosciences of California Inc.'s shares have surged 12.42% and 13.86%, respectively. Additionally, from the beginning of 2014, the stock has gained 2.10%. The company's stock is trading below its 50-day moving average. The stock's 50-day moving average of $5.45 is above its 200-day moving average of $5.34. Pacific Biosciences of California Inc.'s stock has a Relative Strength Index (RSI) of 54.74. Sign up and read the free notes on PACB at:
On Tuesday, shares in Thermo Fisher Scientific Inc. traded between $120.64 and $122.02 before ending the session 0.89% lower at $120.71. The stock reported a trading volume of 1.06 million shares, below its three months average volume of 1.73 million shares. Shares of the company traded at a PE ratio of 32.24. Although, Thermo Fisher Scientific Inc.'s shares have lost 0.90% in the last three trading sessions, it has advanced 4.29% in the previous three months and 8.41% on YTD basis. The stock is trading above its 50-day and 200-day moving averages of $120.52 and $115.93, respectively. Moreover, shares of Thermo Fisher Scientific Inc. have an RSI of 52.68. The complimentary notes on TMO can be downloaded as in PDF format at:
Lexicon Pharmaceuticals Inc.'s stock advanced 2.00%, to close the day at $1.53. The stock recorded a trading volume of 0.75 million shares, below its three months average volume of 1.23 million shares. The stock oscillated between $1.50 and $1.54 during the session. Over the last three trading sessions and over the past three months, Lexicon Pharmaceuticals Inc.'s shares have gained 3.38% and 15.91%, respectively. However, the stock has lost 14.95% since the start of this year. The company's stock is trading below its 50-day and 200-day moving averages. Lexicon Pharmaceuticals Inc.'s 200-day moving average of $1.73 is above its 50-day moving average of $1.58. Additionally, the stock has an RSI of 46.43. Register for free on Investor-Edge and access the latest research on LXRX at:
On Tuesday, shares in Vical Inc. recorded a trading volume of 0.34 million shares, lower than its three months average volume of 0.90 million shares. The stock ended the day at $1.27, which was 0.78% below its previous day's closing of $1.28, and registered an intraday range of $1.25 and $1.29. Vical Inc.'s shares have advanced 1.60% in the previous three trading sessions, 3.25% in the last three months and 7.63% on YTD basis. The stock is trading above its 50-day and 200-day moving averages of $1.24 and $1.26, respectively. Furthermore, shares of Vical Inc. have an RSI of 52.39. The complete research on VICL is available for free at:
Jazz Pharmaceuticals PLC's stock gained 1.66%, to close Tuesday's session at $163.56, after oscillating between $159.52 and $163.98. The stock recorded a trading volume of 0.70 million shares, below its three months average volume of 0.87 million shares. Jazz Pharmaceuticals PLC's shares have surged 14.77% in the last one month and 20.82% in the previous three months. Additionally, from the beginning of 2014, the stock has gained an upside of 29.24%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $147.63 is greater than its 200-day moving average of $139.42. Further, Jazz Pharmaceuticals PLC's stock traded at a PE ratio of 76.23 and has an RSI of 67.40. Free in depth research on JAZZ is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.